of all car-t cell trials registered since 2001, more than half are being conducted in china.
.
eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.
published on: may 17, 2018 | last updated: may 17, 2018 5:42 pm pdt
.
.
u.s.
.
schneider said that he is "not aware of any relevant risk of the drug" and that his team has "not observed side effects in thousands of treated animals."
.
. november 17, 2014
.